Efficacy of Neoadjuvant Chemotherapy in Lobular and Rare Subtypes of Breast Cancer

Basit Öğe Kaydı
dc.authoridYILMAZ, Mesut/0000-0003-1466-3887
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.authoridKAPAGAN, TANJU/0000-0001-9381-1934
dc.contributor.authorSeber, Erdogan Selcuk
dc.contributor.authorIriagac, Yakup
dc.contributor.authorCavdar, Eyyup
dc.contributor.authorKaraboyun, Kubilay
dc.contributor.authorAvci, Okan
dc.contributor.authorYolcu, Ahmet
dc.contributor.authorGurdal, Sibel Ozkan
dc.date.accessioned2024-10-29T17:59:06Z
dc.date.available2024-10-29T17:59:06Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractObjective: To determine the predictive factors for the pathological complete response (pCR) in patients with non-ductal invasive breast cancer (ND-BC) receiving neoadjuvant chemotherapy.Study Design: Observational study.Place and Duration of the Study: Departments of Medical Oncology, Tekirdag Namik Kemal University, Sirnak State Hospital, Aydin Adnan Menderes University, Marmara University, Bakirkoy Sadi Konuk Hospital, Basaksehir Cam and Sakura Hospital, Sakarya University, Balikesir Ataturk Hospital, Turkiye, from April 2016 to December 2022.Methodology: A total of 222 non-metastatic breast cancer patients who received neoadjuvant chemotherapy were included in this retrospective multicentric study. The clinicopathologic data were obtained from the hospitals' electronic-record-system. The logistic regression models were used to identify predictive factors for pCR.Results: One hundred and twenty-six patients (56.8%) had invasive lobular carcinoma and 28 patients (12.6%) had signet ring cell/mucinous carcinoma. A total of 45 patients (20.3%) achieved pCR. The pCR rate was 14.3% for lobular carcinoma and 17.9% for signet ring cell/mucinous carcinoma. The univariate analysis showed that estrogen receptor-negative tumours (p = 0.017), high Ki-67 (p = 0.008), high histologic grade (p<0.001), HER2+ expression (p<0.001), and non-lobular histologic type (p = 0.012) were predictive factors for pCR. The multivariate model revealed that HER2 expression (p<0.001) and Ki-67 (p = 0.005) were independent predictors.Conclusion: Neoadjuvant chemotherapy demonstrated effectiveness in ND-BC patients, leading to favourable pCR rates and enabling breast-conserving surgery. Predictive markers for pCR varied depending on histologic types, with HER2 expression, ER status, Ki-67, and histologic grade showing significance in non-ductal subtypes, while HER2 status alone was predictive in lobular carcinoma.
dc.identifier.doi10.29271/jcpsp.2024.01.37
dc.identifier.endpage41
dc.identifier.issn1022-386X
dc.identifier.issn1681-7168
dc.identifier.issue1en_US
dc.identifier.pmid38185958
dc.identifier.scopus2-s2.0-85182030033
dc.identifier.scopusqualityQ3
dc.identifier.startpage37
dc.identifier.urihttps://doi.org/10.29271/jcpsp.2024.01.37
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14627
dc.identifier.volume34
dc.identifier.wosWOS:001140254200003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherColl Physicians & Surgeons Pakistan
dc.relation.ispartofJcpsp-Journal of The College of Physicians and Surgeons Pakistan
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectNeoadjuvant chemotherapy
dc.subjectNon-ductal breast cancer
dc.subjectLobular carcinoma
dc.titleEfficacy of Neoadjuvant Chemotherapy in Lobular and Rare Subtypes of Breast Cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu